UBS AM’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-90,932
| Closed | -$3.72M | – | 2887 |
|
|
2024
Q2 | $3.72M | Buy |
90,932
+6,095
| +7% | +$249K | ﹤0.01% | 1657 |
|
|
2024
Q1 | $3.59M | Buy |
84,837
+193
| +0.2% | +$8.16K | ﹤0.01% | 1406 |
|
|
2023
Q4 | $3.59M | Buy |
84,644
+13,697
| +19% | +$581K | ﹤0.01% | 1411 |
|
|
2023
Q3 | $1.55M | Buy |
70,947
+9,982
| +16% | +$218K | ﹤0.01% | 1740 |
|
|
2023
Q2 | $1.49M | Hold |
60,965
| – | – | ﹤0.01% | 1818 |
|
|
2023
Q1 | $1.49M | Buy |
60,965
+9,649
| +19% | +$235K | ﹤0.01% | 1818 |
|
|
2022
Q4 | $1.62M | Buy |
51,316
+1,348
| +3% | +$42.5K | ﹤0.01% | 1632 |
|
|
2022
Q3 | $1.41M | Sell |
49,968
-12,227
| -20% | -$346K | ﹤0.01% | 1776 |
|
|
2022
Q2 | $1.64M | Buy |
62,195
+28,373
| +84% | +$750K | ﹤0.01% | 1706 |
|
|
2022
Q1 | $1.18M | Hold |
33,822
| – | – | ﹤0.01% | 2047 |
|
|
2021
Q4 | $1.1M | Buy |
33,822
+550
| +2% | +$17.8K | ﹤0.01% | 2165 |
|
|
2021
Q3 | $982K | Buy |
+33,272
| New | +$982K | ﹤0.01% | 2175 |
|